



## miRagen Therapeutics to Present at the Needham and Company 16th Annual Healthcare Conference

March 28, 2017

BOULDER, Colo., March 28, 2017 (GLOBE NEWSWIRE) -- Miragen Therapeutics, Inc. (Nasdaq:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide a company overview at the Needham and Company 16<sup>th</sup> Annual Healthcare Conference on Tuesday, April 4, 2017, at 5:00 p.m. ET. The conference is being held at the Westin New York Grand Central hotel in New York City.

The presentation will be webcast live and may be accessed by visiting the "Investors" section of the Company's web site at [www.investors.miragentherapeutics.com](http://www.investors.miragentherapeutics.com). A replay of the webcast will be available for 90 days.

### **About Miragen Therapeutics, Inc.**

Miragen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen's two lead product candidates, MRG-106 and MRG-201, are currently in Phase 1 clinical trials. miRagen's clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in several blood cancers. miRagen's clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis. In addition to miRagen's clinical programs, it is developing a pipeline of pre-clinical product candidates. The goal of miRagen's translational medicine strategy is to progress rapidly to first in human studies once it has established the pharmacokinetics, pharmacodynamics and safety of the product candidate in pre-clinical studies. For more information, please visit [www.miragentherapeutics.com](http://www.miragentherapeutics.com).

For information on clinical trials please visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

miRagen Investor Contact:

Adam Levy  
Chief Business Officer  
(720) 407-4595  
[alevy@miragenrx.com](mailto:alevy@miragenrx.com)



Source: Miragen Therapeutics, Inc.